Inhibikase Therapeutics, Inc. (NYSE:IKT - Get Free Report) shares rose 4.9% during mid-day trading on Monday . The stock traded as high as $2.40 and last traded at $2.36. Approximately 175,997 shares were traded during mid-day trading, a decline of 20% from the average daily volume of 220,970 shares. The stock had previously closed at $2.25.
Analysts Set New Price Targets
Separately, HC Wainwright lowered Inhibikase Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th.
Get Our Latest Report on Inhibikase Therapeutics
Inhibikase Therapeutics Price Performance
The firm has a market capitalization of $164.39 million, a PE ratio of -0.89 and a beta of 1.04. The firm has a 50-day simple moving average of $2.51 and a 200-day simple moving average of $2.33.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Jefferies Financial Group Inc. purchased a new position in Inhibikase Therapeutics in the fourth quarter worth about $48,000. Alpine Global Management LLC purchased a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at about $48,000. Soleus Capital Management L.P. purchased a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at about $20,556,000. Squarepoint Ops LLC purchased a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at about $92,000. Finally, Stonepine Capital Management LLC purchased a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at about $3,680,000. 3.81% of the stock is owned by hedge funds and other institutional investors.
Inhibikase Therapeutics Company Profile
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Further Reading
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
